Townsend Adam J. 4
4 · Apellis Pharmaceuticals, Inc. · Filed May 4, 2023
Insider Transaction Report
Form 4
Townsend Adam J.
Chief Commercial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-05-03−5,000→ 282,500 totalExercise: $15.09Exp: 2028-11-15→ Common Stock (5,000 underlying) - Exercise/Conversion
Common Stock
2023-05-03$15.09/sh+5,000$75,450→ 80,995 total - Sale
Common Stock
2023-05-03$82.71/sh−5,000$413,550→ 75,995 total
Footnotes (2)
- [F1]This is a scheduled exercise and sale from an established 10b5-1 plan.
- [F2]This option was granted on November 16, 2018 and vests as to 25% of the shares underlying the options on the first anniversary of Mr. Townsend's date of hire, November 16, 2018, with the remaining 75% of the shares underlying the option vesting in equal monthly installments thereafter through the fourth anniversary of his date of hire, subject to continued service.